A recent clinical study, known as the FOCUS trial, has shown that the use of melphalan in combination with a hepatic delivery system (HDS) leads to improved outcomes for patients diagnosed with metastatic uveal melanoma. Uveal melanoma is a rare but aggressive form of eye cancer that often spreads to the liver. In the trial, patients who received melphalan/HDS experienced higher survival rates and better tumor response compared to those who received the best alternative care available. The hepatic delivery system allows for targeted administration of melphalan directly to the liver, which is the most common site of metastasis for this cancer. The FOCUS trial's findings suggest that this treatment approach may offer a new therapeutic option for patients with limited alternatives. The study was reported by Targeted Oncology.